Barclays PLC Trims Position in Twist Bioscience Co. (NASDAQ:TWST)

Barclays PLC cut its position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 17.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 126,367 shares of the company's stock after selling 26,672 shares during the quarter. Barclays PLC owned approximately 0.21% of Twist Bioscience worth $5,873,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Stifel Financial Corp lifted its stake in Twist Bioscience by 11.8% in the third quarter. Stifel Financial Corp now owns 6,967 shares of the company's stock worth $315,000 after purchasing an additional 734 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in Twist Bioscience during the 3rd quarter valued at about $34,000. Franklin Resources Inc. grew its position in Twist Bioscience by 3.4% during the 3rd quarter. Franklin Resources Inc. now owns 252,064 shares of the company's stock worth $11,756,000 after acquiring an additional 8,308 shares during the last quarter. Beaird Harris Wealth Management LLC purchased a new position in Twist Bioscience in the 3rd quarter worth approximately $95,000. Finally, Oddo BHF Asset Management Sas bought a new stake in Twist Bioscience in the third quarter valued at approximately $3,302,000.

Analysts Set New Price Targets

TWST has been the topic of several analyst reports. Barclays decreased their target price on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. Guggenheim set a $50.00 target price on Twist Bioscience in a research note on Friday, March 28th. Scotiabank reaffirmed an "outperform" rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Robert W. Baird boosted their target price on Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a research note on Tuesday, February 4th. Finally, JPMorgan Chase & Co. raised their price target on Twist Bioscience from $35.00 to $40.00 and gave the stock an "underweight" rating in a research note on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Twist Bioscience has an average rating of "Moderate Buy" and an average price target of $52.80.

Insider Buying and Selling at Twist Bioscience

In other news, CEO Emily M. Leproust sold 5,200 shares of the company's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total transaction of $256,620.00. Following the transaction, the chief executive officer now directly owns 667,318 shares of the company's stock, valued at $32,932,143.30. This represents a 0.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Patrick John Finn sold 2,058 shares of the stock in a transaction on Wednesday, April 23rd. The shares were sold at an average price of $39.99, for a total value of $82,299.42. Following the sale, the chief operating officer now directly owns 265,460 shares in the company, valued at $10,615,745.40. This trade represents a 0.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,432 shares of company stock worth $1,038,170. Insiders own 3.01% of the company's stock.

Twist Bioscience Stock Down 0.6 %

Shares of NASDAQ TWST traded down $0.22 during trading on Tuesday, reaching $39.68. The company had a trading volume of 942,892 shares, compared to its average volume of 979,957. Twist Bioscience Co. has a 12-month low of $30.32 and a 12-month high of $60.90. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. The business's 50-day moving average is $39.51 and its 200 day moving average is $44.26. The stock has a market cap of $2.37 billion, a PE ratio of -11.74 and a beta of 2.34.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business had revenue of $88.70 million during the quarter, compared to analysts' expectations of $86.96 million. During the same period in the previous year, the company earned ($0.75) earnings per share. The business's revenue for the quarter was up 24.1% compared to the same quarter last year. As a group, equities analysts forecast that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.